Merck SciBrunch Therapeutics $2.1B Deal Structure Breakdown

$400M Upfront for a Preclinical Asset: What Merck Sees in SciBrunch's KRAS G12D Molecular Glue

$400M upfront for a preclinical small molecule is not normal. On September 28, 2026, Merck announced a license agreement with SciBrunch Therapeutics for SPR2015, a molecular glue inhibitor of KRAS G12D in the ON state, valuing the deal at up to $2.1B including $1.7B in development, regulatory, and commercial milestones. Royalty terms remain undisclosed. This is, by any reasonable benchmark, the most aggressive preclinical licensing deal in the KRAS space to date — and it tells you exactly how Merck views the competitive clock ticking on its oncology portfolio refresh.

Deal Structure Breakdown

The SciBrunch Therapeutics Merck deal terms break down as follows:

The upfront-to-TDV ratio here is 19.0%. For context, the median upfront-to-TDV ratio for preclinical oncology licenses tracked across Solidus sits closer to 8–12%. SciBrunch extracted nearly double the typical proportion in cash at signing. That is a direct reflection of two things: (1) competitive tension from multiple potential licensees, and (2) Merck's strategic urgency.

The $1.7B milestone tail is substantial but not unusual for a deal of this headline size. What matters is the implied structure. With the asset still preclinical, the bulk of milestones are almost certainly back-loaded toward Phase 3 data readouts, regulatory approvals across indications, and tiered commercial sales thresholds. Merck is paying a premium to get in early, but the risk-sharing architecture is standard: SciBrunch gets rewarded for de-risking; Merck caps downside by tying the majority of economics to clinical and commercial proof points.

The undisclosed royalties are worth flagging. In deals of this magnitude with undisclosed tiers, industry convention and comparable transactions suggest a range likely in the low-to-mid teens on net sales, potentially escalating to high teens at upper commercial thresholds. Given the $400M upfront, SciBrunch had leverage to push royalty floors higher than the typical 8–10% baseline for preclinical assets. We estimate effective blended royalties are likely north of 12%, though neither party has confirmed this.

Competitive Context — Why Merck and Why SPR2015

Merck's oncology franchise is built on KEYTRUDA, which generated over $25B in 2025 revenue. The problem is obvious: KEYTRUDA's composition-of-matter patent expires in 2028, and biosimilar erosion will begin hitting U.S. revenues by 2029. Merck has been on a sustained acquisition and licensing spree to fill the gap, spending over $30B on oncology deals since 2023. The SciBrunch Therapeutics Merck deal structure fits squarely into this replacement strategy.

SPR2015 is not just another KRAS inhibitor. It is a molecular glue inhibitor targeting KRAS G12D in the ON state — a mechanism of action that differentiates it from the first wave of KRAS G12C covalent inhibitors (sotorasib, adagrasib) and from conventional KRAS G12D inhibitors that primarily engage the OFF state. KRAS G12D mutations are found in approximately 36% of pancreatic cancers, 12% of colorectal cancers, and 4% of non-small cell lung cancers. The ON-state mechanism is critical because KRAS G12D spends a far greater proportion of its cycling time in the GTP-bound (ON) conformation compared to G12C, making OFF-state inhibitors inherently less effective against this mutation.

Molecular glue degraders and molecular glue-based inhibitors have become one of the most competitive modalities in oncology drug development. The mechanism co-opts cellular machinery to achieve target engagement that traditional occupancy-based inhibitors struggle with. For Merck, securing a differentiated molecular glue approach to KRAS G12D accomplishes three objectives simultaneously:

• Pipeline differentiation: Merck lacked a credible KRAS G12D-specific asset. Revolution Medicines, Mirati (now BMS), and Eli Lilly have all staked positions in KRAS, but none with a confirmed molecular glue mechanism against G12D ON-state.
• Combination potential with IO backbone: KRAS inhibitors are expected to combine synergistically with PD-1/PD-L1 checkpoint inhibitors. Merck can run KEYTRUDA combinations immediately upon SPR2015 entering the clinic, leveraging existing trial infrastructure.
• Competitive blocking: By locking up SPR2015, Merck denies this asset — and potentially this mechanism class — to Roche, AstraZeneca, and Pfizer, all of whom are actively building KRAS portfolios.

The timing is not coincidental. Multiple KRAS G12D programs from competitors entered Phase 1 in 2025–2026, compressing the window for Merck to secure a best-in-class candidate at the preclinical stage before clinical data from rivals reset valuation expectations upward. Paying $400M upfront for a preclinical asset looks expensive in isolation. In the context of a $25B revenue cliff and a narrowing competitive window, it is a calculated move to avoid paying $3–5B for the same asset 18 months later with Phase 1 data in hand.

What This Means for Similar Assets

If you are a biotech founder or BD lead sitting on a preclinical small molecule oncology asset, this deal recalibrates your expectations — but only if your program checks specific boxes.

The SciBrunch Therapeutics Merck deal terms set a new high-water mark for preclinical oncology licensing upfronts. The $400M upfront is roughly 2–3x the median for preclinical oncology small molecule licenses over the past three years. But context matters enormously. SPR2015 sits at the intersection of three premium-value attributes:

• Validated target with large patient populations: KRAS G12D is one of the highest-value undrugged oncology targets remaining. Assets against well-validated but undrugged targets command 40–60% upfront premiums over assets against established targets with existing approved therapies.
• Differentiated mechanism: Molecular glue inhibition is a scarce modality with demonstrated clinical translation (see: cereblon-based molecular glues in hematology). Mechanism novelty compresses competition and expands buyer willingness to pay.
• Strategic fit for a specific buyer under revenue pressure: The KEYTRUDA cliff created a uniquely motivated buyer. Not every licensee will face this dynamic.

For a more typical preclinical small molecule oncology asset — say, a next-generation kinase inhibitor against an already-drugged target — upfront expectations should remain in the $30–80M range, with TDV of $500M–$1.2B. If your asset has genuine mechanism differentiation against a high-value target with no approved therapy, the SciBrunch deal supports pushing upfront demands into the $150–300M range, particularly if you can generate competitive tension among two or more strategic buyers.

Royalty benchmarks remain harder to pin down given the undisclosed terms here, but the broader dataset on Solidus shows preclinical oncology licenses averaging 8–12% base royalties, with escalators to 15–18% on blockbuster sales tiers. The SciBrunch deal likely sits at the upper end or above this range given the upfront magnitude.

Bottom line: The SciBrunch–Merck deal is not a new normal for all preclinical oncology assets. It is a pricing signal for the narrow category of differentiated-mechanism programs against high-value, undrugged targets where multiple pharma buyers have identified strategic urgency. If that describes your asset, your valuation just went up. If it does not, do not use this deal to justify inflated expectations — your counterparty's BD team will have the same comp set you do.

Benchmark Your Deal

Benchmark your own oncology deal against 1,400+ comparable transactions using the Ambrosia calculator. Filter by phase, modality, target class, and therapeutic area to see where your upfront, milestones, and royalty terms rank against verified deal data — including the SciBrunch Therapeutics Merck deal structure and every other major oncology license from the past five years.